Fulgent Genetics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Fulgent Genetics hat ein Gesamteigenkapital von $1.1B und eine Gesamtverschuldung von $2.9M, was einen Verschuldungsgrad von 0.3% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $1.2B bzw. $103.2M.

Wichtige Informationen

0.3%

Verhältnis von Schulden zu Eigenkapital

US$2.91m

Verschuldung

Zinsdeckungsgradn/a
BargeldUS$305.70m
EigenkapitalUS$1.13b
GesamtverbindlichkeitenUS$103.24m
GesamtvermögenUS$1.23b

Jüngste Berichte zur Finanzlage

Recent updates

Fulgent Genetics: Growth Is Returning

Jun 06

Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

May 10
Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 07
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Mar 01
Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Fulgent Genetics: Buy Growth Ahead Below Liquidation Value

Feb 21

Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Jan 17
Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Dec 14
Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Aug 09
Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 09
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Apr 19
Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Jan 15
Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Dec 28
Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Nov 16
What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Oct 27
Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Wait For Fulgent Genetics To Grow Up

Oct 13

We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Sep 19
We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Sep 05
Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Fulgent Genetics: Poised To Survive Its Post-Covid Hangover

Jul 26

Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Jul 21
Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Jun 04
Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Fulgent Is Putting Its Cash Bonanza To Work

May 15

These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

May 04
These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

Fulgent Genetics: Now The Going Could Get Much Tougher

Apr 10

Fulgent Genetics: COVID Bolstered The Underlying Business

Mar 17

Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business

Feb 27

Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy

Feb 09

Fulgent Genetics: Sell Volatility

Jan 26

Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet

Jan 25
Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet

Fulgent Genetics: Improving Outlook, But Shares Aren't Quite A Buy

Jan 09

Fulgent Genetics: Undervalued, High Growth, And A COVID Hedge To Boot

Dec 20

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: FLGTDie kurzfristigen Aktiva des Unternehmens ($386.5M) übersteigen seine kurzfristigen Passiva ($75.9M).

Langfristige Verbindlichkeiten: FLGTDie kurzfristigen Vermögenswerte des Unternehmens ($386.5M) übersteigen seine langfristigen Verbindlichkeiten ($27.3M).


Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: FLGT über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: FLGTDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0% auf 0.3% gestiegen.

Schuldendeckung: FLGTDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (1451.3%).

Zinsdeckung: Es liegen nicht genügend Daten vor, um festzustellen, ob die Zinszahlungen von FLGT auf seine Schulden durch EBIT gut gedeckt sind.


Bilanz


Entdecken Sie finanziell stabile Unternehmen